Since cells harboring KRAS mutation are the main reason for EGFR-TKI resistance with the continuous expression of KRAS, we speculated that the combination treatment of MA and EGFR-TKI osimertinib was a strategy to inhibit KRAS-mutated lung cancer cells. Here, KRAS is linked to lung carcinoma.